Insiders · ZNTL

ZNTL insider transactions

Zentalis Pharmaceuticals Inc. (ZNTL) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for ZNTL

• 12d
  Director Campbell Shannon was granted 114,200 shares (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 12d
  SEC Form 3 filed by new insider Campbell Shannon

  3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 118d
  Chief Medical Officer Bruns Ingmar sold $7,998 worth of shares (3,297 units at $2.43), decreasing direct ownership by 9% to 33,332 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 118d
  PAO and PFO Vultaggio Vincent sold $97,557 worth of shares (40,224 units at $2.43), decreasing direct ownership by 22% to 146,506 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 118d
  CEO & President Eastland Julia Marie sold $21,239 worth of shares (8,755 units at $2.43), decreasing direct ownership by 10% to 79,133 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 124d
  PAO and PFO Vultaggio Vincent sold $7,875 worth of shares (3,096 units at $2.54), decreasing direct ownership by 2% to 186,730 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 150d
  SEC Form 4 filed by PAO and PFO Vultaggio Vincent

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 150d
  SEC Form 4 filed by Chief Legal Officer Bucher James B

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 150d
  SEC Form 4 filed by Chief Medical Officer Bruns Ingmar

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 150d
  SEC Form 4 filed by CEO & President Eastland Julia Marie

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 151d
  Large owner Walters Group bought $7,751,968 worth of shares (6,459,973 units at $1.20) (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 151d
  New insider Walters Group claimed ownership of 7,050,000 shares (SEC Form 3)

  3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 175d
  Large owner Matrix Capital Management Company, Lp sold $9,975,000 worth of shares (7,500,000 units at $1.33) (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 250d
  SEC Form 4 filed by Chief Legal Officer Bucher James B

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 259d
  SEC Form 3 filed by new insider Bucher James B

  3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 355d
  Director Walker Luke Nathaniel was granted 57,603 shares, increasing direct ownership by 66% to 144,284 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 355d
  Director Skvarka Jan was granted 57,603 shares, increasing direct ownership by 39% to 207,154 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 355d
  Director Johnson David Michael was granted 57,603 shares, increasing direct ownership by 30% to 250,421 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 355d
  Director Kariuki Enoch was granted 57,603 shares, increasing direct ownership by 72% to 137,365 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 355d
  Director Myers Scott Dunseth was granted 57,603 shares, increasing direct ownership by 20% to 338,795 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 404d
  Director Myers Scott Dunseth bought $29,373 worth of shares (21,000 units at $1.40), increasing direct ownership by 8% to 281,192 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 481d
  Chief Medical Officer Bruns Ingmar bought $45,656 worth of shares (20,000 units at $2.28), increasing direct ownership by 120% to 36,629 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 488d
  PAO and Interim PFO Vultaggio Vincent was granted 158,586 shares and sold $4,476 worth of shares (2,615 units at $1.71), increasing direct ownership by 461% to 189,826 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 488d
  Chief Scientific Officer Lackner Mark sold $24,591 worth of shares (14,368 units at $1.71) and was granted 335,907 shares, increasing direct ownership by 168% to 512,856 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 488d
  Chief Legal Officer Paul Andrea was granted 934,041 shares and sold $22,643 worth of shares (13,230 units at $1.71), increasing direct ownership by 614% to 1,070,784 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 488d
  Chief Medical Officer Bruns Ingmar was granted 16,629 shares (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 488d
  CEO & President Eastland Julia Marie was granted 59,388 shares, increasing direct ownership by 208% to 87,888 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 489d
  Director Skvarka Jan bought $103,446 worth of shares (60,000 units at $1.72), increasing direct ownership by 67% to 149,551 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 489d
  Director Walker Luke Nathaniel bought $24,966 worth of shares (14,200 units at $1.76), increasing direct ownership by 20% to 86,681 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 489d
  CEO & President Eastland Julia Marie bought $49,345 worth of shares (28,500 units at $1.73) (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 521d
  Chief Scientific Officer Lackner Mark sold $13,762 worth of shares (4,411 units at $3.12), decreasing direct ownership by 2% to 191,317 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 552d
  SEC Form 4 filed by Chief Medical Officer Bruns Ingmar

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 552d
  SEC Form 4 filed by CEO & President Eastland Julia Marie

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 572d
  Director Myers Scott Dunseth was granted 260,192 shares (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 572d
  SEC Form 3 filed by new insider Bruns Ingmar

  3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 572d
  SEC Form 3 filed by new insider Eastland Julia Marie

  3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 572d
  SEC Form 3 filed by new insider Myers Scott Dunseth

  3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 612d
  Principal Accounting Officer Vultaggio Vincent sold $5,098 worth of shares (1,603 units at $3.18), decreasing direct ownership by 5% to 33,855 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 717d
  Director Skvarka Jan was granted 41,581 shares, increasing direct ownership by 87% to 89,551 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 717d
  Director Kariuki Enoch was granted 41,581 shares, increasing direct ownership by 109% to 79,762 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 717d
  Director Johnson David Michael was granted 48,429 shares, increasing direct ownership by 34% to 192,818 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 738d
  Gallagher Cam sold $114,972 worth of shares (9,597 units at $11.98), decreasing direct ownership by 1% to 633,680 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 740d
  Walker Luke Nathaniel was granted 72,481 shares (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 740d
  SEC Form 3 filed by new insider Walker Luke Nathaniel

  3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 760d
  Hausman Diana sold $42,353 worth of shares (3,356 units at $12.62), decreasing direct ownership by 0.89% to 373,876 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 788d
  New insider Vultaggio Vincent claimed ownership of 35,458 shares (SEC Form 3)

  3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 847d
  Epperly Melissa B, sold $29,435 worth of shares (2,573 units at $11.44), decreasing direct ownership by 0.57% to 451,449 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 847d
  Gallagher Cam sold $13,419 worth of shares (1,173 units at $11.44), decreasing direct ownership by 0.18% to 643,277 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 854d
  Hausman Diana was granted 337,500 shares, increasing direct ownership by 849% to 377,232 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 854d
  Lackner Mark was granted 141,000 shares and sold $18,291 worth of shares (1,585 units at $11.54), increasing direct ownership by 248% to 195,728 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 854d
  Paul Andrea was granted 112,500 shares and sold $38,197 worth of shares (3,310 units at $11.54), increasing direct ownership by 268% to 149,973 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 854d
  Gallagher Cam was granted 192,500 shares and sold $133,310 worth of shares (11,552 units at $11.54), increasing direct ownership by 39% to 644,450 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 854d
  Epperly Melissa B, was granted 75,000 shares and sold $100,040 worth of shares (8,669 units at $11.54), increasing direct ownership by 17% to 454,022 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 854d
  Blackwell Kimberly was granted 250,000 shares and covered exercise/tax liability with 20,655 shares, increasing direct ownership by 90% to 484,145 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 887d
  Lackner Mark was granted 40,000 shares, increasing direct ownership by 245% to 56,313 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 887d
  New insider Lackner Mark claimed ownership of 16,313 shares (SEC Form 3)

  3 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 900d
  Bunker Kevin D. gifted 24,158 shares, decreasing direct ownership by 3% to 834,931 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 938d
  Johnson David Michael bought $167,943 worth of shares (17,000 units at $9.88), increasing direct ownership by 13% to 144,389 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 938d
  Blackwell Kimberly bought $51,448 worth of shares (5,000 units at $10.29), increasing direct ownership by 2% to 254,800 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)
• 976d
  Brownstein Carrie sold $207,298 worth of shares (10,628 units at $19.50), decreasing direct ownership by 9% to 105,685 units (SEC Form 4)

  4 - Zentalis Pharmaceuticals, Inc. (0001725160) (Issuer)